Summary:
A Single Blind, two period, placebo-controlled, randomized, sequential, multiple ascending dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DS-7309 in subjects with Type 2 Diabetes Mellitus.
Qualified Participants Must:
• Be Male or a non-pregnant, non-breastfeeding female
•
Be between 18 and 65 years of age
•
Have a BMI between 19 and 36 kg/m2